1. Treatment with the Thiazolidinedione (BRL 49653) Decreases Insulin Resistance in Obese Zucker Hindlimb
- Author
-
Tpd Eldershaw, Stephen Rattigan, R. E. Buckingham, M. A. Cawthorne, Michael G. Clark, and Eric Q. Colquhoun
- Subjects
Male ,medicine.medical_specialty ,animal structures ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Hindlimb ,Muscle mass ,Biochemistry ,Rosiglitazone ,Endocrinology ,Insulin resistance ,Internal medicine ,medicine ,Animals ,Thiazolidinedione ,Muscle, Skeletal ,business.industry ,Biochemistry (medical) ,General Medicine ,medicine.disease ,Rats ,Rats, Zucker ,Perfusion ,Thiazoles ,Adipose Tissue ,Thiazolidinediones ,Zucker Rats ,Insulin Resistance ,medicine.symptom ,business ,Weight gain - Abstract
Hindlimbs of mature age obese fa/fa Zucker rats were perfused and found to be markedly insulin-resistant when compared to the hindlimbs of age-matched lean Fa/? animals. Hindlimb analysis also showed a greater content of fat and a lower content of muscle in the obese. Treatment of the obese animals for 7 days with the thiazolidinedione, BRL 49653 (3 mumol/kg/day) significantly decreased the insulin resistance of the hindlimb and significantly increased the rate of weight gain in the whole rat. However, the decreased insulin resistance due to BRL 49653 could not be accounted for by an increase in the proportion of hindlimb muscle to fat or by an increase in the hindlimb muscle mass perfused.
- Published
- 1995